<SEC-DOCUMENT>0001654954-21-012896.txt : 20211207
<SEC-HEADER>0001654954-21-012896.hdr.sgml : 20211207
<ACCEPTANCE-DATETIME>20211207092314
ACCESSION NUMBER:		0001654954-21-012896
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20211207
FILED AS OF DATE:		20211207
DATE AS OF CHANGE:		20211207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IM Cannabis Corp.
		CENTRAL INDEX KEY:			0001792030
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40065
		FILM NUMBER:		211474847

	BUSINESS ADDRESS:	
		STREET 1:		1 ADELAIDE STREET EAST, UNIT 801
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 2V9
		BUSINESS PHONE:		416-256-4202

	MAIL ADDRESS:	
		STREET 1:		1 ADELAIDE STREET EAST, UNIT 801
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 2V9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>imcc_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2021 Issuer Direct Corporation -->
<title>imcc_6k</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">
UNITED STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">
SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Washington, D.C. 20549</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">
Form 6-K</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
month of <font style="text-decoration: underline;"><font style="font-weight: bold;">December</font></font><font style="font-weight: bold; text-decoration: underline">,
2021</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number: <font style="font-weight: bold; text-decoration: underline">001-40065</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 24px">
IM Cannabis Corp.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
Name of Registrant as Specified in Charter)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Kibbutz Glil Yam, Central District, Israel 4690500</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Address
of principal executive offices)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form
20-F&#xA0; &#x25A1;&#xA0; Form 40-F <font style="font-family: Times New Roman">&#x22A0;</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Note</font>: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Note</font>: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home
country exchange on which the registrant's securities are traded,
as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant's
security holders, and, if discussing a material event, has already
been the subject of a Form 6-K submission or other Commission
filing on EDGAR.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<br>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="page_2">
<!--anchor--></a>SIGNATURE</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: middle;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">IM
CANNABIS CORP.</font> <font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 0%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: middle;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Registrant)</font>
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 0%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 5%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 0%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">December
7, 2021</font></div>
</td>
<td style="vertical-align: middle; width: 5%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: middle; width: 45%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
/s/ Oren Shuster</font></div>
</td>
<td style="vertical-align: middle; width: 0%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Name:</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Oren
Shuster</font></div>
</td>
<td style="vertical-align: middle; width: 0%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Title:</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Executive Officer and Director</font></div>
</td>
<td style="vertical-align: middle; width: 0%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT INDEX</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-family: inherit; font-size: inherit;">
<tr>
<td style="width: 10%;">
<div><font style="font-size: 13px;"><a href="imcc_ex991.htm">99.1</a><br></font></div>
</td>
<td style="width: 90%;">
<div><font style="font-size: 13px;">Press release dated December 7,
2021<br></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>imcc_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2021 Issuer Direct Corporation -->
<title>imcc_ex991</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;
<font style="font-weight: bold">Exhibit 99.1</font></font></div>
</div>
</div>
<div>
<div style="text-align: right"><font>&#xA0;<br></font></div>
<img src="imc_ex991000.jpg"></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">
IM Cannabis to Launch WAGNERS Brand in Germany</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 16px">
IM Cannabis expects to export premium, indoor-grown Canadian
cannabis in 2022 to the rapidly evolving German medical cannabis
market</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Toronto, Canada; Glil Yam, Israel and Bad Oldesloe, Germany &#x2013;
December 7, 2021 &#x2013;</font> <font style="text-decoration: underline; color: #0000FF">IM Cannabis
Corp</font>. (the &#x201C;<font style="font-weight: bold">Company</font>&#x201D; or &#x201C;<font style="font-weight: bold">IM Cannabis</font>&#x201D;) (CSE: IMCC, NASDAQ:
IMCC), a global cannabis company with operations in Israel, Canada,
and Germany is pleased to announce plans to launch its popular
Canadian WAGNERS brand in the German medical cannabis market in
2022 and begin exports of premium, indoor-grown dried flower from
IMC Canada&#x2019;s cultivation facility in 2022, subject to
regulatory approval. These plans are consistent with the
Company&#x2019;s vertically integrated, multi-country strategy and
follow the Company&#x2019;s recently announced launch of WAGNERS in
Israel and the receipt of an import permit for Canadian cannabis
products from the Israeli Ministry of Health.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">To
learn more about WAGNERS, please visit <font style="text-decoration: underline; color: #0000FF">WAGNERS - Well Made
Weed (wagnersweed.com)</font><font style="font-size: 70%; vertical-align: top"><a href="#ref.KGD1">1</a></font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="imc_ex991001.jpg"></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Oren Shuster, CEO of IM Cannabis stated</font>, &#x201C;With the
rapid growth in demand for premium indoor-grown Canadian cannabis
and an increasing number of German medical patients not relying on
government re-imbursement, we are excited to launch our popular
WAGNERS brand to medical patients in Germany. We continue to lay
our foundation in Germany, currently one of the largest medical
cannabis markets in the world, which is expected to rapidly expand
as Germany&#x2019;s new elected government enact broad regulatory
reform of cannabis use. Leveraging our global supply chain, IM
Cannabis continues to focus on growing our business substantially
in Germany in the near term and being well-positioned through brand
recognition for eventual regulatory reform.&#x201D;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
IM Cannabis&#x2019; Global Infrastructure for International
Shipments</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">IM
Cannabis operates in Germany through Adjupharm GmbH, the
Company&#x2019;s fully licensed EU-GMP subsidiary
(&#x201C;<font style="font-weight: bold">Adjupharm</font>&#x201D; or
&#x201C;<font style="font-weight: bold">IMC Germany</font>&#x201D;),
which recently completed construction of a new, state-of-the-art
logistics center that will allow the Company to execute all aspects
of its supply chain including the repackaging of bulk cannabis. The
Company expects that the logistics center will augment the
Company&#x2019;s distribution capabilities. Additionally, the
Company&#x2019;s operations in Germany are expected to serve as the
center of a broader long-term European strategy. Since being
acquired by IM Cannabis, Adjupharm has upgraded its production and
storage capacities to meet the increase in medical cannabis volumes
from new supply agreements. With the completion of the logistics
center, IM Cannabis has now doubled its footprint in Germany to
approximately 8,000 square feet, upgraded its production facilities
with state-of-the-art technology, and increased its storage
capacity to seven tons of cannabis. With the logistics center in
operation, new sources of supply extending its portfolio to include
premium products, some of them exclusive, and a wide network of
distribution partners, the Company expects to fortify and grow its
presence in the German market.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">IM
Cannabis operates in Canada through Trichome Financial Corp.
(&#x201C;<font style="font-weight: bold">Trichome</font>&#x201D;) and
its subsidiaries Trichome JWC Acquisition Corp.
(&#x201C;<font style="font-weight: bold">TJAC</font>&#x201D;) and MYM
Nutraceuticals Inc. (&#x201C;<font style="font-weight: bold">MYM</font>&#x201D;, and together with Trichome
and TJAC, &#x201C;<font style="font-weight: bold">IMC
Canada</font>&#x201D;). IMC Canada&#x2019;s Manitou Facility in
Kitchener, Ontario is a 115,000 square foot indoor cultivation
facility located just one hour away from Toronto, that has achieved
accreditation as Good Agricultural and Collection Practices
(&#x201C;GACP&#x201D;) by virtue of its ICann G.A.P certification,
and it serves as the Company&#x2019;s global cultivation hub for
export and further processing in Germany and Israel.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About IM Cannabis Corp.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">IM
Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international
cannabis company providing premium products to medical patients and
adult-use recreational consumers. IM Cannabis is one of the very
few companies with operations in Israel, Germany, and Canada, the
three largest federally legal markets. The ecosystem created
through its international operations leverages the Company&#x2019;s
unique data-driven perspective and product supply chain globally.
With its commitment to responsible growth and financial prudence,
and the ability to operate within the strictest regulatory
environments, the Company has quickly become one of the leading
cultivators and distributors of high-quality cannabis
globally.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The IM
Cannabis ecosystem operates in Israel through its commercial
relationship with Focus Medical Herbs, which cultivates, imports,
and distributes cannabis to medical patients, leveraging years of
proprietary data and patient insights. The Company also operates
medical cannabis retail pharmacies, online platforms, distribution
centres and logistical hubs in Israel that enable the safe delivery
and quality control of IM Cannabis products throughout the entire
value chain. In Germany, the IM Cannabis ecosystem operates through
Adjupharm GmbH (&#x201C;<font style="font-weight: bold">Adjupharm</font>&#x201D; or &#x201C;<font style="font-weight: bold">IMC Germany</font>&#x201D;), where it also
distributes cannabis to pharmacies for medical patients. In Canada,
IM Cannabis operates through Trichome Financial Corp.
(&#x201C;<font style="font-weight: bold">Trichome</font>&#x201D;) and
its subsidiaries Trichome JWC Acquisition Corp (&#x201C;<font style="font-weight: bold">TJAC</font>&#x201D;) and MYM Nutraceuticals Inc.
(&#x201C;<font style="font-weight: bold">MYM</font>&#x201D;, and
together with Trichome and TJAC, &#x201C;<font style="font-weight: bold">IMC Canada</font>&#x201D;), where it cultivates
and processes cannabis for the adult-use market at its Ontario,
Nova Scotia, and Quebec facilities under the WAGNERS and Highland
Grow brands.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Disclaimer for Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release contains &#x201C;forward-looking information&#x201D;
and &#x201C;forward-looking statements&#x201D; within the meaning of
applicable Canadian and United States securities laws
(collectively, &#x201C;forward-looking information&#x201D;).
Forward-looking information are often, but not always, identified
by the use of words such as &#x201C;seek&#x201D;,
&#x201C;anticipate&#x201D;, &#x201C;believe&#x201D;,
&#x201C;plan&#x201D;, &#x201C;estimate&#x201D;, &#x201C;expect&#x201D;,
&#x201C;likely&#x201D; and &#x201C;intend&#x201D; and statements that
an event or result &#x201C;may&#x201D;, &#x201C;will&#x201D;,
&#x201C;should&#x201D;, &#x201C;could&#x201D; or &#x201C;might&#x201D;
occur or be achieved and other similar expressions. Forward-looking
information in this press release includes, without limitation,
statements relating to expectation regarding the growth of the
German medical cannabis market, the launch and market reception of
the WAGNERS brand in the German medical market, the demand for
premium quality indoor-grown cannabis among German medical cannabis
patients, the upgrades and enhancements to Adjupharm&#x2019;s
facilities and operations, the enhanced shareholder value achieved
through distribution of Canadian-grown cannabis in multiple markets
and the margins in markets outside of Canada, and the
Company&#x2019;s business and strategic plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Forward-looking
information is based on assumptions that may prove to be incorrect,
including but not limited to the ability of the Company to execute
its business plan, the continued growth of the medical and/or
recreational cannabis markets in the countries in which the Company
operates or intends to operate, the Company maintaining &#x201C;de
facto&#x201D; control over Focus Medical in accordance with IFRS 10,
Focus Medical maintaining its existing Israeli medical cannabis
propagation and cultivation licenses, the expected
decriminalization and/or legalization of adult-use recreational
cannabis in Israel, Adjupharm maintaining its license, permit and
authorization to conduct cannabis activities, and the expected
regulatory reform in Germany and timing of such reform. The Company
considers these assumptions to be reasonable in the circumstances.
However, forward-looking information is subject to business and
economic risks and uncertainties and other factors that could cause
actual results of operations to differ materially from those
expressed or implied in the forward-looking information. Such risks
include, without limitation: the Company having to rely on third
party cannabis producers to supply Adjupharm with product to
successfully fulfil previously announced sales agreements and
purchase commitments; the ability of the Company to comply with
applicable government regulations in a highly regulated industry;
unexpected changes in governmental policies and regulations
affecting the production, distribution, manufacture, import, export
or use of medical and/or recreational cannabis, as applicable, in
Israel, Germany and Canada; any change in the political environment
which would negatively affect the decriminalization and/or
legalization of recreational cannabis in Israel and Germany;
unexpected changes in governmental policies and regulations
affecting the production, distribution, manufacture, import, export
or use of medical and/or recreational cannabis, as applicable, in
Israel and Canada; any unexpected failure of any of Focus Medical,
Adjupharm, Trichome or MYM to maintain in good standing or renew
all required licenses, permits or authorizations to conduct
cannabis activities in their respective jurisdictions; reliance on
the Company&#x2019;s commercial facilities in Germany and Canada and
any unexpected failure of the Company and its subsidiaries to
maintain such commercial facilities in good standing with all
applicable regulations, including all required licenses and
permits; the ability of the Company and its subsidiaries to
maintain ancillary business licenses, permits and approvals
required to operate effectively; unexpected disruptions to the
operations and businesses of the Company, Adjupharm, Focus Medical,
Trichome or MYM as a result of the COVID-19 global pandemic or
other disease outbreaks including a resurgence in the number of
cases of COVID-19, which has occurred in certain locations and the
possibility of which in other locations creates ongoing uncertainty
that could result in restrictions to contain the virus being
re-imposed or imposed on a more strict basis, including
restrictions on movement and businesses; and the perceived effects
of medical cannabis products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Please
see the other risks, uncertainties and factors set out under the
heading &#x201C;Risk Factors&#x201D; in the Company&#x2019;s
management&#x2019;s discussion and analysis dated November 15, 2021
and annual information form dated April 26, 2021 filed with
Canadian securities regulators and which are available on the
Company&#x2019;s issuer profile on SEDAR at www.sedar.com. Any
forward-looking statement included in this press release is made as
of the date of this press release and is based on the beliefs,
estimates, expectations and opinions of management on the date such
forward-looking information is made. The Company does not undertake
any obligation to update forward-looking statements except as
required by applicable securities laws. Investors should not place
undue reliance on forward-looking statements. Forward-looking
statements contained in this press release are expressly qualified
by this cautionary statement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Investor &amp; Media Contacts:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px;">

<table cellpadding="0" cellspacing="0" style="text-align: justify; width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 47%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Maya
Lustig,</font></div>
</td>
<td style="vertical-align: top; width: 53%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 47%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Director
Investor &amp; Public Relations</font></div>
</td>
<td style="vertical-align: top; width: 53%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 47%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
IM Cannabis</font></div>
</td>
<td style="vertical-align: top; width: 53%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">KCSA
Strategic Communications</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 47%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Tel.
+972-54-677-8100</font></div>
</td>
<td style="vertical-align: top; width: 53%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Kathleen
Heaney</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 47%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline"><font style="color: #0000FF; font-family: Times New Roman; font-size: 13px">maya.l@imcannabis.com</font></font></div>
</td>
<td style="vertical-align: top; width: 53%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline"><font style="color: #0000FF; font-family: Times New Roman; font-size: 13px">imcannabis@kcsa.com</font></font></div>
</td>
</tr></table>
<font style="font-family: Times New Roman; font-size: 13px;"><br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
<a name="ref.KGD1">1</a></font> <font style="font-size: 13px">Canadian regulations permit only the export of
cannabis for medical or scientific purposes. Exports to Germany
will comply with the Canadian Cannabis Act.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>imc_ex991000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 imc_ex991000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! 6,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY1[\C\ZSOA',\G@"VB8D_9YI8E^F[/\ 6NLGO)S>&UM(4DD1 \C2/M50<X'
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M-?\ T,5W7QC_ .2=77_7>'_T,5POP(_Y&35?^O-?_0Q7=?&/_DG5U_UWB_\
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M^N-<O+GP_8Z+(V;6SEDEC&><OC^7./\ >-?1_P 2= ;Q#X)O;>&,O=0#[1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>imc_ex991001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 imc_ex991001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M8U3\9W/]:P-GM2B-?44N5=A\S.B3QAXM3D:OJ1^LC'^=3KXX\9 8&J7Q_P"
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M'(S\L?I4UV"(1P/O>E5I,FSB'_323^24'N9?_!^8]-4NBH_TJ<?]M&_QI_\
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M'<GI73VWAN&U.=6NML@ZVMKAW_X$WW5^G)K.I5A27--V-J.'JUY<M*-V8R$
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MTDL$IBBD(!65 " >.0PSCZ=>P *VLF)M9L94N()96(,OENCD$-QN>/"L<=\
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M^'U/#&.<X/H1D5EV]MJ^EGSX89X@1CS(UWJ1]1D&HSJMX-16\DF#7"# +@8
MP1C'XFN55%%WDFGI^9U2P\IQ<8236K^;5B[,WG:!>K;ZA)?;&1Y6F# HN>-N
M<]2/7M6I)&'URY$;7JRR1$&5@#!&"HYZ_P"36!=ZU>7MNUO)+&L3'++&@7=1
M(=<U&)@PNI(<<\;$_'H/SJE5C?1-_P!,SEA)VO.26_7O;R2>WD36U_;Z78Z<
M&WR2?-,Z1L-N&^7YL_[/;CZUDILD.H&&-DC-I.54G)4;#U--G.FV )O+Y99
M>;>S(D;/N_W1^IK(U#7I[N%K6VC6SLB>88B27_WVZM_+VK>CAZLI1<E9(BM7
MHPC*-/WG+=]/ZU,LU:M/^/B+_?'\ZJ5;L^;F#WD7^=>C4/ELX^&'J5Y:@J:7
MH*KYYK(\)#ZD@XN(O9U_G4(-*"0P(Z@Y% UN:NN\>(M1'_3S)_Z$:TK#Q-J=
MM8I9Q/%Y**47,>3@^_XU2_M2RU%BVJ69$['FZM,(Y/JR'Y6_2K<&C1W'.G:G
M:W.>D4C>1)^3\'\#0:RYN9RIO?[R?3M<U'2K8P6<J)&7WX:,,<X [_055MEO
MHG?4[<'-NVYI< A2?8]>OI5F;1]2M1^_L+E!_>,9(_,<5-;:M)8Z>]DL:$/*
M)&WG@X*G!'_ ?7O2,(RDFE4;26Q$UUK,%]=:F9 ERA\F9QY>1C:I&WV^4$@=
M>.M94LKRRR2R'+NQ9CCJ2<DUL7.HF]2Y2.S427'E[O*9F^Z!SMYYR#S_ +3#
MG.:KKH&IN@D>T:WA[RW)$28^K8_2@<KS=HW91BO[JWAEAAG>..88D53@.,8Y
M_,U:M58Z!J38.T2P<XXS\_'ZT_R=)T\YGG.I3#_EE;DI$/\ ><\M_P ! ^M5
MKS4;B^$:2;8X(O\ 501+MCC^@]?<\T#^#XG\C,O_ /CT;ZC^=4E_X\)?^NJ?
MR>KE]_QZ-]1_.J:_\>$O_75/_07H/5R[^$_4H2=:;]*5_O4V@] =6QX;YN=1
M'KIER/\ QRL:K-A?W&G70N+8H'VE&#H&5E/!4@]0:!&SX7N8(9[E91;"62,+
M$TI564YYV.ZLBG']X 'U'?KDLG34#=S06UU>)IDEQ:PM;1JY=6'WUC)5R 20
M1U Z9%<<DVA:B1YT$VESGK);#S8#]4)W+^!/TK0L] OHITN-$O;6\DC;<C6<
MX253Z[&VL/R-,#4T;4;W7=7L_M\%L^WST%SY"IG,+?*Q P0,9]ORJUHVBV\-
MMI=O)<6.H*=3=R;9_,4D0%E0D@=U''O5*[U/Q7!>07%_%=F2W#>6)[3"C<I5
MC@* >">:Q[?4KRSLXK2W81B*Z%U&X!WB0+M'MC';%(#H-(OYO$L"R:X4G^S:
MA:^5(R 8$CD-'P/NG ./:ECO]5(GGUYI52'4[8VQN%V[)!-\^PG^$(#G'&,&
MLR\G\0>(8E@33I#$'\TI:V916<_QM@<GW)J&ZTR]F=9/$&L1VYC& EQ.;B8#
MT"*21^)%,#/UF*R2ZG-M??:I9)G8F*,B-02< ,>6/(Z#'N:F\1AEUR565E81
M0Y5A@@^2G44X:M:::,:+:NDXX^W76&E'^XOW8_KR?>LAW>1V>1V=V.69CDL?
M4FD,CEZ#ZT]O^/%/^NK_ /H*TR7H/K3F_P"/)/\ KJ_\EH HN>:04-UI* '5
ML:)SINMKZV@/Y2+6+FKFGZC/ITSO"L3K(GER1S1AT=>#@@_3M0!OZ+;+JGAV
M?3(KNUBNS=K*B3R;-P"8X]36_HVEW.D:7K%G=Z4NI2I) S6J$G((.""!GCKT
MKE4.@:B?F6;2ICU*@SP?E]]?_'JVM-T[7K(L^A:A'=*P&?L%R&) Z9C;#?FM
M C0$*RZ?KD?]E2Z>C?9IVM"#N$2L0YZ XX)JYI^E:4-7TB^TBVFAA<3O_I#-
M\VU0 >2<#+=:QGU/Q/I^L+J5S%=)=*GEDS6Q563K@@  \_C5>]\3:IJ%Y-/-
MY3--;M:^6J':J-C.T9ZG'4YI@=#-I$QB@M//@ENKC29+4&)\J[QLK  \<X_E
M7*OIMYH$FFWMT3;W#S[EB8C<JJ5^8^@))'X4^TM_$,MM!;V-K>F*"4S1-% 0
M4<\9#XX_/%+=Z;+).UQX@UF**7&"GF?:9R/3:IP/Q84 9^IS?:_$-W+"_G"6
MY8QLO.X%N,?A3_$ QXCU,>EU+_Z$:E.L0V*&/1+9K4D8:[E8-<,/8CA!_N\^
M]9&23DDDGDYI%"&EA_X^X?\ KHO\Z0T0_P#'U#_UT7^= &GI8/V0X_O_ -!1
M4VB@?8FR,_O#_(44R&2>(?\ D?=5_P"PI+_Z--<[+TKHO$)_XK[5?^PI+_Z-
M-<W+TKTH['FO<@S2@TTFC-,!^:O:7:K>W\5N\GEHV2S<9P 3@#NQQ@#N2!6>
M*E6D!TJ>&M0.&@A=U(0A)1Y4F6W84J3PWRDXST*D=<5-;G5]/C\R W]M$,9:
M,NB\@$<CCH0?Q%8MI>W%LICBF98V#@H/NG>NUN.F2,#/7@>@KH8/$MSB/S8(
M)&282AP"K??5B.#C!V@=.G%/WO4'R[["KXIUU>FJW!P>=Q#?S%12>)];E!SJ
M]UCU23;_ .@XIMQJC7%Q:2LCM]F;(,LI=W^;=@L1T[#CBI+G7I;H.;B'S&$W
MFQ$RM^[(S@<YR.<XSVHY5_*+F>W,4[C3]6N9=T]K=O(5W!IPP)&&;@MUR$;'
MKCBK:Z%%8QK<ZE+F/YQB/[FY=PVELC)RA&!C.1AL9(KRZ_>[G^S[+4.79EB!
M.6<@LV7+$'*CD'C''4YRY99)Y3)+(SN26)8Y.2<D_B>:+28[Q7F+<>2+J7[,
M6\C>?+W#G;GC--B_UR?[PIE/C_UB?[PHJ? _0JC_ !8^J-\_>3Z_T-02]:F;
MJG^]_0U!-]ZOCWT/TQ;O^NA%FES3:,T%$@-.:0QA< <G!9LX ]S48ZU/&>:<
M6D[M7)FG*-D[$MM>Q$X;*,%!.>W&?Y5<;[+*3O\ )8CKNP:K(J,?F4'K^O6I
MQ:H1E689;=V///M[UJG2O=-HY)QKVM)*2_KY ;*TSG[/%S_LBCR+6(;Q%"H'
M?:!3VMT:%8B3M4Y^O.:C, '1W"YW #'!H]I=:S8O8I.\:<?PW(I+J+@*V\G[
MH7OT_P 15=)9IW1X\"/OSU_3W'IT-6O(C#!M@+#^(\GZ_7FG4G.G'X5?U-%3
MK3?[R5EV7^8E;WAG[]S]%_K6%BMWPU_K+GZ+_6N+$?PV1F/^[2^7YHW%_P!9
M<_\ 70?^@+4#=:F4_O;K_KH/_0%JNYYKS9;GRH9IV:BSS3@:0$JU4DU8VM[(
MDL)$"$#=M8.1MW,XXP4'0\\8/L*M(>:G&&0HZAD8896&01[BKIRA%^\KB:;V
M8MGKFG7=N"9U0'JDN/\ 9ZD97^->_4XZT[^SM OG4BTTR=V!8;4C8D=SQ]#^
M5(^F6=V&,L?S,<E@><[E8^W)12>.<?6GQZ-"LZ2>?,P5HWVL$Y9/NG(4$?AC
M/XFNA3HI7IR<7_78BTNJ3(VT#04/.F6 /7#1K_6GE])TEC&HM+1@NXJBJAQS
MS@<]C^1IUSI%K=37$TA<2S(J;E/W,9Y Z9Y[@TATZ(R>9-)-,Y8,^]@%<C[I
M*J .!QT[#.2,T.JI)<\Y/R_KYARM;)&=<>((!*B0(TNZ38SD$ ')& .K-A6(
M'&0.,\ V=+_M+RG;4BN]F!55(^3C!' '&1D<DX;!Z<VK>U@LX]EM"D2X .P8
MS@8&3U/'K4M9U*E/EY:<?F]_^ 4E*]VPKS3Q[_R,2?\ 7LO_ *$U>EUYKX]_
MY&&/_KV7_P!":N[)O]Z^3-:>YS-[]_\ X O_ *"*H'K5Z]^__P  3_T$5GDU
M]6;"TN:CI0: )DR>!U/3)Q722^')XG;[.YD1"X9I4\H,% )=23ADYX;(ZCU%
M<TE7;.YFM9-\$KQ,<9*'&<$,/U /U HU$[]#>@M=7TV1_*BO;=D)W-#N&,'!
MR5X[58'B;6U&/[4N#QG#D-_,&H[/Q)=11E&C@D4X(RF"I#.V1@@#F1NWIZ4Z
M^UA[ZS$#1L!F,Y>4OMV)L&P8&T$<GKDX]*+7W0TFWJ@;Q3K394:I*/4)M4_H
M*K3KK&IJDDWVVYC<X1Y2Q0G('!/'4U<FUYIHO(FM]UO]F2#RQ*1]WR_F]!DQ
MC@ =3SWJJ=>NXW1[=(H)$V#S%!8L$4H@(8D8"DC@#/?-%K;(+/HA\'AV15,M
M\YBBCD"S+& 6C'&XL>B@ Y!YZ$?7+OQ:"Z/V(GR=HX/9@,'N<@D9'/>F3W$U
MPV9IGD("CYCGH,#\AQ4-&H)/=A5NQ_X^8/\ KHO\ZJU9LO\ CY@_ZZ+_ #J*
MFQY.<?##U*TO057)J>7H/I58FLCP4.!IP-19IP- S0TVV%Y>QP,Y12"20.3@
M$X [DXP!W)%;":#> DQ1F10%.UQL<$@M@J3PV!G&>XZYKG$K1M+R>!#&DK+&
MP8%.JX88;CIR .?8>E >Y:TD;<+ZI8Q^9$;RW3/WD+JOYCCO^M6!XCUE1_R$
MIS_O,#_.B#Q%/NA>2W@=XY?.W!2I)W[R.N,9XX X^E0RZBTEU:3%&/V8J1OD
M+L^&W<L?R'' I$.2BO=FQ9?$.KRKSJESC_9DV_RJK+8:G<R$RV]R\@7=NF!!
MQ@G^+V5OKBK<VLO* TT6^1)?-B8N?D. !P<YQ@'K55]9NU)^S%+922=L0/4D
M,3EB3G(ZY_F<A2<6_>DV3IHT%GB;4I"T0W\1_<++GY=V02<JPQQSCG%8TPC$
M\GDL3%N.PD8.W/%#LTC;G8LQ).6.>IR?UYIF*"9RBU:*L5K[_CT;ZC^=4E_X
M\)?^NJ?^@O5Z^_X]'SZC^8JB.-/E_P"NT?\ Z"]![&7?PGZE!S\QJ/-.DZFH
M\T'H#\THJ,&G@T 3I@<FN@ET&]M85DD2-QL+N%;E,*&((8#D;AG&1GC.:YY#
M6U;:UJ"*4:[>:-E*&.?$JD$J2,-G^ZOOQ0!=MM1UBTA5[:\OXHBVQ3'*X4M_
M=&#C/3BK#>)/$*,T;:K?AEZJ96!']:+;Q)>0P) L-MY,?^K14*;3AP2"I!!/
MF/SGC(QC IDFMRM9268B A<,,L[,XR$'WB<X_=@X^Z>A' P 12W.N:HZQ//J
M%T78*$:1V!)!(&"<<@$_0$U#%X>OIK=9E2.-'5V7?D [0Q.3C"_<(Y(.<<5/
M)XAOO*$:B *(T0'R@2 L1BSD]258]<]L8QBL^ZU"\NRYFN'8.Y=@,*&8DG)
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MZ[1_^@O6CJ Q:/\ 4?S%9P_X\)?^NT?_ *#)0>[EO\)^IG2]:BJ63[U1&@]
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MS<?3L<@,&E@I*SZN0T;.H1L!FVG ZN,$^_YT",Y;><](93]$-3+:777[+/\
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MRJR,,$'-);W#6MRDR*C[>JN,JP(P0?8@D5(L[W6J1S2!06E7A1A5 (  ]@,
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M6_[Z-.R'>78!O[,O_?/_ ->G /G[R_\ ?/\ ]>D"*?[W_?1IX5!_>_[[/^-
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MVWEA5$AELU55!.<JS9S_ -]"O4R[ U:-;VD[;%TY+F.#O!S_ , 3_P!!%9I
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81+9D?V+J"#><![=E)X'J**^D**87/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
